Raymond James Financial
AUTL

Raymond James Financial’s Autolus Therapeutics AUTL Stock Holding History

Raymond James Financial’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$456 – 5097
2025
Q2 		$456 Buy
+200
New +$331 ﹤0.01% 6681

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's AUTL Position: Q3 2025 in Review

Raymond James Financial sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 200 shares — an estimated $456 sold.

Raymond James Financial first reported a position in AUTL in Q2 2025 and held it in 1 quarter. The position peaked at $456 in Q2 2025. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • Raymond James Financial reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 200 Autolus Therapeutics shares in Q3 2025, an estimated $456.
  • Raymond James Financial first reported a position in Autolus Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Autolus Therapeutics position peaked at $456 in Q2 2025.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.